SUNSHINE TOUR ANTI-DOPING PROGRAM
PROHIBITED LIST 2017

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES – IN AND OUT OF COMPETITION

PROHIBITED SUBSTANCES

S0 Non-Approved Substances
S1 Anabolic Agents
S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics
S3 Beta$_2$Agonists
S4 Hormone and Metabolic Modulators
S5 Diuretics and other Masking Agents
S6 Stimulants
S7 Narcotics
S8 Cannabinoids
S9 Glucocorticoids
S10 Beta Blockers

PROHIBITED METHODS

M1 Manipulation of Blood and Blood Components
M2 Chemical and Physical Manipulation
M3 Gene Doping

WARNING - IMPORTANT NOTE about using the PROHIBITED LIST and SUPPLEMENTS

There is no complete list of prohibited substances.

The following list (which is based on the World Anti-Doping Agency Prohibited List Standard 2017) shows examples of the prohibited classes. Note this includes the statement: "and other substances with similar chemical structure or similar biological effects(s)".

Do **not** rely upon this list to rule out any prohibited ingredient, particularly from a supplement. Any substance that is chemically related to the class- even if not listed as an example is also prohibited. Dietary supplements are not well regulated and may cause an adverse analytical finding or rule violation. Athletes have tested positive and been charged with a doping violation because of a supplement contaminated or containing a prohibited substance that is not clearly identified on the label. Testing of Supplements may reduce the risk but will not **guarantee** that the supplement is entirely free of unknown or unidentified contaminants. Athlete remains liable!

Therefore any product containing a dietary supplement is taken at your own risk.

Check the status of a licensed medication using a drug information website and keep a record of the response to the enquiry.

If you cannot find it – don't assume it's permitted

PROHIBITED SUBSTANCES

The use of any drug should be limited to medically justified indications

S0. NON-APPROVED SUBSTANCES

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (i.e. drugs under pre-clinical or clinical development or discontinued, designer drugs, veterinary medicines) is prohibited at all times.

S1. ANABOLIC AGENTS

Anabolic Agents are prohibited.

1. Anabolic Androgenic Steroids (AAS)

a. Exogenous[1] AAS, including:

1-androstendiol (5α-androst-1-ene-3β,17β-diol)**; 1-androstendione** (5α-androst-1-ene-3,17-dione)**; 1-Testosterone** (17β –hydroxy-5α-androst-1-en-3-one); **4-Hydroxytestosterone** (4,17β-dihydroxyandrost-4-en-3-one); **bolandiol** (estr-4-ene-33β,17β-diol)**; bolasterone; calusterone; clostebol; danazol** ([1,2] oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol)**; dehydrochlormethyltestosterone** (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)**; desoxymethyltestosterone** (17α-methyl-5α-androst-2-en-17β-ol)**; drostanolone; ethylestrenol** (19-norpregna-4-en-17α-ol)**; fluoxymesterone; formebolone; furazabol** (17α-methyl[1.2.5]oxadiazolol[3',4':2,3]-5α-androstan-17β-ol)**; gestrinone; mestanolone; mesterolone;; metandienone** (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)**;metenolone; methandriol; methasterone** (17β-hydroxy-2α, 17α-dimethyl-5α-androstan-3-one)**; methyldienolone** (17β-hydroxy-17α-methylestra-4,9-dien-3-one)**; methyl-1-testosterone** (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one)**; methylnortestosterone** (17β-hydroxy-17α-methylestr-4-en-3-one)**; methyltestosterone; metribolone** (methyltrienolone, 17β-hydroxy -17α-methylestra-4,9,11-trien-3-one); **mibolerone; norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol** (17β-[(tetrahydropyran-2-yl)oxy]-1'*H*-pyrazolol[3,4:2,3]-5α-androstane)**; quinbolone; stanozolol; stenbolone; tetrahydrogestrinone** (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one)**; trenbolone** (17β-hydroxyestr-4,9,11-trien-3-one) and other substances with a similar chemical structure or similar biological effect(s).

[1] **Exogenous** refers to a substance which is not ordinarily capable of being produced by the body

b. Endogenous[2] AAS when administered exogenously:

19-norandrostenediol (estr-4-ene-3,17-diol); **19-norandrostenedione** (estr-4-ene-3,17-dione); **androstenediol** (androst-5-ene-3β,17β-diol)**; androstenedione** (androst-4-ene-3,17-dione)**; boldenone; boldione** (androsta-1,4-diene-3,17-dione)**;dihydrotestosterone** (17β-hydroxy-5α-androstan-3-one)**; nandrolone[3]** (19-norandrostenedione)**; prasterone** (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one)**; testosterone** and the following metabolites and isomers including but not limited to:

3β-Hydroxy-5α-androstan-17-one; 5α-androst-2-ene-17-one; 5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane-3β,17α-diol; 5α-androstane-3β,17β-diol; 5 β-androstane-3α, 17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-androstenediol (androst-4-ene-3β,17β-diol)**; 5-Androstenedione** (androst-5-ene-3,17-dione); **7-keto-DHEA; 19-norandrosterone; 19-noretiocholanolone; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; androsterone; epi-dihydrotestosterone; epitestosterone; etiocholanolone;**

[2] **Endogenous** refers to a substance which is capable of being produced by the body naturally

[3] **Nandrolone** and **19-nandrostenedione** are prohibited at concentrations greater than 2.5 nanograms per mililiter

2. Other Anabolic Agents, including but not limited to:

Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine and **ostarine), tibolone, zeranol, zilpaterol.**

S2 PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES AND MIMETICS

The following substances and other substances with similar chemical structure or similar biological effect(s) are prohibited:

1. **Erythropoietin-Receptor agonists:**
   - **1.1 Erythropoiesis-Stimulating Agents (ESAs) including** e.g. **darbepoietin** (dEPO); **erythropoietins (EPO), EPO-Fc; EPO-mimetic peptides** (EMP), e.g. **CNTO 530** and **peginesatide, GATA inhibitors, e.g. K-11706; methoxy polyethylene glycol-epoetin beta (CERA); Transforming Growth Factor-β(TGF-β) inhibitors, e.g. sotatercept, luspatercept;**
   - **1.2 Non-erythropoietic EPO-Receptor agonists,** e.g. **ARA-290, asialo EPO** and **Carbamylated EPO;**

2. **Hypoxia- inducible factor** (HIF) **stabilizers,** e.g. **cobalt, molidustat and roxadustat** (FG-4592); and **HIF activators,** e.g. **argon and xenon**

3. **Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH)** and their releasing factors, e.g. **buserelin, gonadorelin** and **leuprorelin**, in males**;**

4. **Corticotrophins** and their releasing factors, e.g. **corticorelin;**

5. **Growth Hormone (GH),** and its releasing factors and its releasing factors including **Growth Hormone Releasing Hormone** (GHRH) and its analogues, e.g. **CJC-1295,** sermorelin and **tesamorelin; Growth Hormone Secretagogues** (GHS), e.g. **ghrelin** and **ghrelin mimetics**, e.g. **anamorelin** and ipamorelin; and **GH-Releasing Peptides** (GHRPs), e.g. **alexamorelin, GHRP-6, hexarelin** and pralmorelin (GHRP-2).

   Additional prohibited growth factors:
   Fibroblast Growth Factors (FGFs), **Hepatocyte Growth Factor** (HGF)**, Insulin-like Growth Factor-1** (**IGF-1)** and its **analogues**; Mechano **Growth Factors** (MGFs)**; Platelet-Derived Growth Factor** (PDGF)**, Vascular-Endothelial Growth Factor** (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

S3. BETA-2 AGONISTS

All selective and non-selective **beta$_2$ agonists** (including all optical isomers) are prohibited, including but not limited to:

Fenoterol; Formoterol; Higenamine*; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Terbutaline and Vilanterol.

Except:

- inhaled **salbutamol** (maximum 1600 micrograms over 24 hours, not to exceed 800 micrograms every 12 hours)
- inhaled **formoterol** (maximum 54 micrograms over 24 hours)
- inhaled **salmeterol** (maximum 200 micrograms over 24 hours).

The presence of salbutamol in urine in excess of 1000ng/ml or formoterol in excess of 40ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an

Adverse Analytical Finding unless the Player proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic inhaled dose up to the maximum indicated above.

NOTE: Terbutaline when administered by inhalation, requires a Therapeutic Use Exemption application. A TUE application should be submitted and a Medical File prepared and submitted on request when a TUE is required, for example to explain an Adverse Analytical Finding.

***Higenamine** is documented to be a constituent of the plant *Tinospora crispa*, which can be found in some dietary supplements and is a non-selective beta-2-agonist.

S4. HORMONE AND METABOLIC MODULATORS

The following **hormones** and **metabolic modulators** are prohibited:

1. **Aromatase inhibitors** including, but not limited to, **4-androstene-3,6,17 trione (6-oxo); aminoglutethimide, anastrozole, androsta-1,4,6-triene-3, 17-dione (androstatrienedione), androsta 3,5-diene-7,17-dione (arimistane); exemestane, formestane, letrozole, testolactone.**

2. **Selective Estrogen Receptor Modulators (SERMs**) including, but not limited to, **raloxifene, tamoxifen, toremifene.**

3. **Other anti-estrogenic substances** including, but not limited to, **clomiphene, cyclofenil, fulvestrant.**

4. **Agents modifying myostatin function(s)** including, but not limited to, **myostatin inhibitors.**

5. **Metabolic modulators:**

   5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. **AICAR**; and **Peroxisome Proliferator Activated Receptor δ** (PPARδ) **agonists,** e.g. **GW 1516**;
   5.2 Insulins and insulin-mimetics
   5.3 Meldonium
   5.4 Trimetazidine

S5. DIURETICS AND OTHER MASKING AGENTS

The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s), including but not limited to:

Desmopressin, probenecid, plasma expanders (e.g. **glycerol**; intravenous administration of **albumin, dextran, hydroxyethyl starch** and **mannitol).**

Diuretics include:

acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. **bendroflumethiazide, chlorothiazide, hydrochlorothiazide**), **triamterene**, **vaptans (**e.g. **tolvaptan);** except for

- Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide
- Local administration of felypressin in dental anaesthesia

The detection in a Player's Sample at all times of any quantity of the following substances subject to threshold limits (i.e. formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or masking agent will be considered as an Adverse Analytical Finding unless the Player has a specific approved Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or masking agent.

S6. STIMULANTS

All stimulants, including all optical isomers (e.g. *d*- and *l*-) where relevant are prohibited, except clonidine and imidazole derivatives for topical/ophthalmic use and those stimulants on the SUNSHINE TOUR Monitoring List.

Stimulants include:

4-Methylhexan-2-amine (methylhexaneamine)*; Adrafinil, amfepramone, amfetamine, amfetaminil, amiphenazole, benzfetamine, benfluorex, benzylpiperazine, bromantan, cathine[1], cathinone and its analogues (e.g. mephedrone, methedrone, α-pyrrolidinovalerophenone) clobenzorex, cocaine, cropropamide, crotetamide, dimethylamphetamine, ephedrine[2], epinephrine[3] (adrenaline), etamivan, etilamphetamine, etilefrine, famprofazone, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, fonturacetam [4-phenylpiracetam (carphedon)], furfenorex, heptaminol, hydroxyamfetamine (parahydroamphetamine), isometheptene, levmetamfetamine, lisdexamfetamine, meclofenoxate, mefenorex, mephentermine, mesocarb, metamfetamine(*d*-), methylenedioxyamphetamine, p-methylamphetamine, methylephedrine[9], methylhexaneamine (dimethylpentylamine), methylphenidate, modafinil, nikethamide, norfenefrine, norfenfluramine, octopamine, oxilofrine (methylsynephrine), pemoline, pentetrazol, phenethylamine and its derivatives, phendimetrazine, phenmetrazine, phenpromethamine, phentermine, prenylamine, prolintane, propylhexedrine, pseudoephedrine[4], selegiline, sibutramine, strychnine, tenamfetamine (methylenedioxyamphetamine), tuaminoheptane** and other substances with a similar chemical structure or similar biological effect(s).

***A number of other synonyms exist for Methylhexamine: 1,3-dimethylamylamine; dimethylpentylamine; methylhexamine; dimethylpentylamine; methylhexamine; methylhexanamine; 1,3-dimethylpentylamine.**
**** Regular food consumption will not yield sufficient levels of phenylethylamine to result in an Adverse Analytical Finding.**

S7. NARCOTICS

The following narcotics are prohibited:

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, nicomorphine; oxycodone, oxymorphone, pentazocine, pethidine.

The presence of hydrocodone, morphine/codeine ratio; tramadol will be **monitored** in order to detect patterns of misuse in golf.

S8. CANNABINOIDS

Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-tetrahydrocannabinol (THC) and cannabimimetics (e.g."Spice", JWH018, JWH073, HU-210) are prohibited.

S9. GLUCOCORTICOSTEROIDS

All glucocorticosteroids are prohibited when administered orally, intravenously, intramuscularly or rectal routes. Their use requires a Therapeutic Use Exemption approval.

---

[1] **Cathine** is prohibited when its concentration in urine is greater than 5 micrograms per millilitre.

[2] **Ephedrine** and **methylephedrine** are prohibited at concentrations in urine greater than 10 micrograms per millilitre.

[3] Local administration (e.g. nasal, ophthalmologic) of **epinephrine (adrenaline)** or co-administration with local anaesthetic agents is **not prohibited.**

[4] **Pseudoephedrine** is prohibited when its concentration in urine is greater than 150 micrograms per millilitre.

Topical preparations when used for auricular, buccal, dermatological (including iontophoresis/phonophoresis), gingival, nasal, ophthalmic and perianal disorders are **permitted**.

Intraarticular, periarticular, peritendinous, epidural, intradermal injections and inhalation routes are **permitted**.

S10. BETA BLOCKERS

The entire class of **Beta Blockers** is prohibited, including but not limited to the following:

Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

PROHIBITED METHODS

M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited:

1. The administration or reintroduction of any quantity of autologous, homologous or heterologous blood or red blood cell products of any origin into the circulatory system**.**

2. Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products, excluding supplemental oxygen)**.**

3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2. CHEMICAL AND PHYSICAL MANIPULATION

The following are prohibited:

1. *Tampering,* or *Attempting* to *tamper*, in order to alter the integrity and validity of *Samples* collected during *Doping Control* is prohibited. These include but are not limited to urine substitution and/or adulteration (e.g. proteases).

2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period are prohibited, except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations.

M3. GENE DOPING

The following, with the potential to enhance sport performance, are prohibited:

1. The transfer of polymers of nucleic acids or nucleic acid analogues;

2. The use of normal or genetically modified cells;

The use of agents that directly or indirectly affect functions known to influence performance by altering gene expression. For example, Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists e.g. GW 1516) and PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) are prohibited.

THE 2017 MONITORING PROGRAM

The following substances are placed on the 2017 Monitoring Program:

1. Stimulants: Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine.

2. Narcotics: Codeine, mitragynine and tramadol.

3. Glucocorticoids: all routes of administration.

4. Angiotensin-II Receptor antagonists: Telmisartan.

5. Beta-2-agonists: any combination of beta-2-agonists.